ArticleNature2022
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 735 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
735citing papers in PubMed, 2 pooled it
114.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
735 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,150 citations in OpenAlex.
- Mortality Assessment in Patients with Cardiovascular Disease and COVID-19: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials.BMC infectious diseases · 2024Pooled it
- Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).The Lancet. Infectious diseases · 2024Trial
- Article
- A knockout screening platform for interferon-stimulated genes in respiratory cells identifies LY6E as a dominant antiviral effector against coronaviruses.bioRxiv : the preprint server for biology · 2026Article
- The conserved QTQTX motif in the SARS-CoV-2 spike protein is dispensable for cleavage and lung cell entry of the emerging variant BA.3.2.Journal of virology · 2026Article
- Convergent use of aminopeptidase N receptor by hedgehog merbecoviruses.Nature microbiology · 2026Article
- Switching Spike Plasticity Shapes ACE2 Engagement Across SARS-CoV-2 Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells.Journal of virology · 2026Article
- Deadbolt Drug Discovery: Locking the Door to Class 1 Viral Entry by Small Molecules.ACS infectious diseases · 2026Review
- Loss-of-function mutation in Omicron variants reduces spike protein expression and attenuates SARS-CoV-2 infection.Nature communications · 2026Article
- Immune evasion, infectivity, and membrane fusion of SARS-CoV-2 variants LP.8.1.1, XEC.25.1, XFG, and NB.1.8.1.Microbiology spectrum · 2026Article
- ACE2-PNA conjugates exploit viral endocytosis for targeted intracellular delivery and exhibit dual antiviral efficacy against SARS-CoV-2.Molecular biomedicine · 2026Article
- Temperature-dependent replication and sensitivity to innate immunity of human coronavirus HKU1.Nature communications · 2026Article
- COVID-19 vaccination induces cross-neutralisation of sarbecoviruses related to SARS-CoV-2.NPJ vaccines · 2026Article
- Repurposing screens reveal a role for PKCη and NF1 in SARS-CoV-2 infection.PLoS pathogens · 2026Article
- miR-29a and miR-15b Modulate SARS-CoV-2 Beta and Omicron Infection in Human Lung Epithelial Cells.International journal of molecular sciences · 2026Article
- Altered infectivity, cell-cell fusion, and immune evasion of SARS-CoV-2 BA.3.2 and LP.8.1 variants.Journal of virology · 2026Article
- Lock out: targeting TMPRSS2 to block influenza and coronaviruses.Journal of virology · 2026Review
675 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
57 authors at 20 institutions in 8 countries.
Bo Meng *Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Adam Abdullahi *Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Isabella A T M Ferreira *Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Niluka Goonawardane *Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Akatsuki Saito *Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan.
Izumi Kimura *Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Daichi Yamasoba *Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Pehuén Pereyra GerberCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Saman FatihiCSIR Institute of Genomics and Integrative Biology, Delhi, India.
Surabhi RathoreCSIR Institute of Genomics and Integrative Biology, Delhi, India.
Samantha K ZepedaDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Guido PapaMRC-Laboratory of Molecular Biology, Cambridge, UK.
Steven A KempCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Mako ToyodaDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Toong Seng TanDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Jin KuramochiKuramochi Clinic Interpark, Utsunomiya, Japan.
Shigeki MitsunagaHuman Genetics Laboratory, National Institute of Genetics, Mishima, Japan.
Takamasa UenoDivision of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
Kotaro ShirakawaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Teresa BreviniDepartment of Medicine, University of Cambridge, Cambridge, UK.
Donna L MalleryMRC-Laboratory of Molecular Biology, Cambridge, UK.
Oscar J CharlesDivision of Infection and Immunity, UCL, London, UK.
CITIID-NIHR BioResource COVID-19 Collaboration
Genotype to Phenotype Japan (G2P-Japan) Consortium
Ecuador-COVID19 Consortium
John E BowenDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Anshu JoshiDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Alexandra C WallsDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Laurelle JacksonAfrica Health Research Institute, Durban, South Africa.
Darren MartinUniversity of Cape Town, Cape Town, South Africa.
Kenneth G C SmithCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
John BradleyDepartment of Medicine, University of Cambridge, Cambridge, UK.
John A G BriggsMax Planck Institute of Biochemistry, Martinsried, Germany.
Jinwook ChoiWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
Elo MadissoonWelcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Kerstin B MeyerWelcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Petra MlcochovaCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Lourdes Ceron-GutierrezAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
Rainer DoffingerAddenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.
Sarah A TeichmannWelcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
Andrew J FisherTransplant and Regenerative Medicine Laboratory, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.
Matteo S PizzutoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Anna de MarcoHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Davide CortiHumabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Myra HosmilloDepartment of Virology, University of Cambridge, Cambridge, UK.
Joo Hyeon LeeWellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.
Leo C JamesMRC-Laboratory of Molecular Biology, Cambridge, UK.
Lipi ThukralCSIR Institute of Genomics and Integrative Biology, Delhi, India.
David VeeslerDepartment of Biochemistry, University of Washington, Seattle, WA, USA.
Alex SigalAfrica Health Research Institute, Durban, South Africa.
Fotios SampaziotisCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Ian G GoodfellowDepartment of Virology, University of Cambridge, Cambridge, UK.
Nicholas J MathesonCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.
Kei SatoDivision of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.
Ravindra K GuptaCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK. rkg20@cam.ac.uk.ORCID http://orcid.org/0000-0001-9751-1808
Cambridge University Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GBUniversidad San Francisco de Quito · ECNational Institute of Infectious Diseases · JPKumamoto University · JPKyoto University · JPUniversity of Miyazaki · JPHokkaido University · JPTokyo Metropolitan Institute of Public Health · JPUniversity of Washington · USInstitute of Genomics and Integrative Biology · INMRC Laboratory of Molecular Biology · GBTokai University · JPVir Biotechnology (Switzerland) · CHWellcome/MRC Cambridge Stem Cell Institute · GBHiroshima University · JPNHS Blood and Transplant · GBUniversity of Guayaquil · ECAfrica Health Research Institute · ZAEuropean Bioinformatics Institute · GB
Funding
TRAINING IN MOLECULAR BIOPHYSICST32GM008268 · NIGMS · UNIVERSITY OF WASHINGTON · PI KOLLMAN, JUSTIN M, ZHENG, NING · 1988 to 2023
$8.6MUnraveling the bat humoral immune response against zoonotic viruses to guide the design of next-generation therapeuticsDP1AI158186 · NIAID · UNIVERSITY OF WASHINGTON · PI VEESLER, DAVID · 2020 to 2024
$5.4MIdentification of the HIV Reservoir in Lymph Nodes Using Single Cell RNA-SeqR01AI138546 · NIAID · KWAZULU-NATAL RESEARCH INSTITUTE TB-HIV · PI SIGAL, ALEXANDER · 2018 to 2022
$721kHoward Hughes Medical InstituteMedical Research Council MC_PC_17230Medical Research Council MC_U105181010Medical Research Council MC_UP_1201/16Medical Research Council MR/P008801/1Medical Research Council MR/T032413/1Medical Research Council MR/W005611/1NIAID NIH HHS DP1 AI158186NIAID NIH HHS HHSN272201700059CNIAID NIH HHS R01 AI138546NIGMS NIH HHS T32 GM008268Wellcome Trust 200594/Z/16/ZWellcome Trust 207498/Z/17/ZWellcome Trust WT108082AIA
Abstract
The SARS-CoV-2 Omicron BA.1 variant emerged in 2021
Indexed as
Membrane FusionVirus InternalizationAdultAgedAged, 80 and overAngiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntibodies, ViralCell LineCell MembraneChlorocebus aethiopsConvalescenceCOVID-19COVID-19 VaccinesFemaleACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmune SeraSerine EndopeptidasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TMPRSS2 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.